Did You Know...
...that the inventor of the electric motor was a blacksmith named Thomas Davenport? Described as "a brilliantly unsuccessful inventor", Davenport invented the first rotary electric motor. In 1836 he headed out -- on foot -- from his Vermont home to file a patent application at the Patent Office in Washington, D.C. By the time he got there, he had squandered away his money and couldn't afford the $30 filing fee so he turned around and went home. When he later mailed in his application with money he'd raised, the Patent office was destroyed in a fire. He did finally get credit for his invention on Feb. 5, 1837.
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 8173824 | Process for producing vitamin D derivative using convergent method There are provided a novel process for producing [{(5Z,7E)-(1S,3R,20S)-1,3-dihydroxy-9,10-secopregna-5,7,10(19),16-tetraen-20-yl}oxy]-N-(2,2,3,3,3-pentafluoropropyl)acetamide, which process is shown in the following reaction scheme: ... | 05/08/2012 |
| 8026379 | Paricalcitol intermediates The present invention relates to a compound and a novel process for the preparation of Paricalcitol intermediates. ... | 09/27/2011 |
| 8013176 | Paricalcitol purification Paricalcitol, a synthetic vitamin D analog, is purified to a purity greater than 99.7% by crystallization from solution in isopropyl acetate solvent, followed by filtration and vacuum drying. Isopropyl acetate appears to be unique among commonly available and pharma... | 09/06/2011 |
| 7795459 | Paricalcitol purification Paricalcitol, a synthetic vitamin D analog, is purified to a purity greater than 99.7% by crystallization from solution in isopropyl acetate solvent, followed by filtration and vacuum drying. Isopropyl acetate appears to be unique among commonly available and pharma... | 09/14/2010 |
| 7524980 | Vitamin Dlactam derivative Compounds expressed by the following formula (1) or pharmaceutically permissible solvate thereof which is effective for treating Paget's disease of bone, hypercalcemia or osteoporosis. In the formula, R1 is a C | 04/28/2009 |
| 7402688 | 2,2-Di-substituted 1alpha,25-dihydroxy-19-norvitamin D derivative A novel 2,2-di-substituted 19-norvitamin D derivative. It is a compound represented by the general formula (I) wherein R1 and R2 are the same or different and each represents hydroxy and A represents hydrogen, or an unsubstituted linear or branched alkyl. | 07/22/2008 |
| 7358092 | Method for the determination of 25-hydroxycholecalciferol in feed A method for quantitative determination of 25-hydroxycholecalciferol in feed is described. The method includes the steps of adding a defined amount of an internal standard which has a mass different from 25-hydroxycholecalciferol and a polarity similar to that compo... | 04/15/2008 |
| 7332482 | Method for treating benign prostatic hyperplasia The use of 1-alpha-fluoro-25-hydroxy-16,23E-diene-26,27-bishomo-20-epi-cholecalciferol, or a pharmaceutically acceptable salt or ester thereof, for the manufacture of a medicament for the prevention and/or treatment of benign prostatic hyperplasia (BPH) and associat... | 02/19/2008 |
| 7323580 | Crystals of a vitamin D derivative and a method for the preparation thereof A compound represented by formula (III): ... | 01/29/2008 |
| 7300925 | 2-ethyl and 2-ethylidene-19-nor-vitamin D compounds Biologically active 19-nor vitamin D analogs substituted at C-2 in the A-ring with an ethylidene or an ethyl group. These compounds have preferential activity on mobilizing calcium from bone and either high or normal intestinal calcium transport activity which allow... | 11/27/2007 |
| 7253293 | Enzymatic method to produce 7-dehydropregnenolone, vitamin D3-like compounds and derivatives thereof Provided herein are enzymatic methods of producing steroid compounds such as 7-dehydropregnenolone, hydroxy derivatives thereof and vitamin D2- and D3-like compounds and derivatives thereof. Also provided are the derivatives of the vitamin D3-like compounds so gener... | 08/07/2007 |
| 7244719 | 2-methylene-19,26,27-trinor-(20S)-1α-hydroxyvitamin Dand its uses This invention discloses 2-methylene-19,26,27-trinor-(20S)-vitamin D analogs, and specifically 2-methylene-19,26,27-trinor-(20S)-1α-hydroxyvitamin D3 and pharmaceutical uses therefor. This compound exhibits pronounced activity in arresting the proliferat... | 07/17/2007 |
| 7241747 | 2-propylidene-19-nor-vitamin D compounds 2-propylidene-19-nor-vitamin D compounds are disclosed as well as pharmaceutical uses for these compounds and methods of synthesizing these compounds. These compounds are characterized by high bone calcium mobilization activity and high intestinal calcium transport ... | 07/10/2007 |
| 7241748 | 17,20(Z)-dehydro vitamin D analogs and their uses This invention discloses 17,20(Z)-dehydro vitamin D analogs, and specifically 17(Z)-1α,25-dihydroxy-17(20)-dehydro-2-methylene-19-nor-vitamin D3 and pharmaceutical uses therefor. This compound exhibits pronounced activity in arresting the proliferation o... | 07/10/2007 |
| 7241909 | 19,26,27-trinor-1α,25-dihydroxyvitamin Dcompounds Compounds of formula 1 are provided where X1, X2, and X3 are independently selected from H or hydroxy protecting groups, and R1 and R2 have the definitions provided herein. Such compounds may be used in preparin... | 07/10/2007 |
| 7241749 | 2α-Methyl and 2β-methyl analogs of 19,26,27-trinor-(20S)-1α-hydroxyvitamin Dand their uses This invention discloses 2α-methyl and 2β-methyl analogs of 19,26,27-trinor-(20S)-1α-hydroxyvitamin D3 and pharmaceutical uses therefor. These compounds exhibit pronounced activity in arresting the proliferation of undifferentiated cells and inducing t... | 07/10/2007 |
| 7241750 | 2-methylene-19-nor-1alpha-hydroxy-17-ene-homopregnacalciferol and its uses This invention discloses 2-methylene-19-nor-17-ene vitamin D analogs, and specifically 2-methylene-19-nor-1α-hydroxy-17-ene-homopregnacalciferol and pharmaceutical uses therefor. This compound exhibits pronounced activity in arresting the proliferation of undiffere... | 07/10/2007 |
| 7241751 | 2α-methyl-19-nor-(20S)-1α-hydroxy-bishomopregnacalciferol and its uses This invention discloses 2α-methyl-19-nor-(20S)-vitamin D analogs, and specifically 2α-methyl-19-nor-(20S)-1α-hydroxy-bishomopregnacalciferol and pharmaceutical uses therefor. This compound exhibits pronounced activity in arresting the proliferation of undifferen... | 07/10/2007 |
| 7241752 | 17,20(E)-dehydro vitamin D analogs and their uses This invention discloses 17,20(E)-dehydro vitamin D analogs, and specifically 17(E)-1α,25-dihydroxy-17(20)-dehydro-2-methylene-19-nor-vitamin D3 and pharmaceutical uses therefor. This compound exhibits pronounced activity in arresting the proliferation o... | 07/10/2007 |
| 7238681 | 2-Methylene-18,19-dinor-1α-hydroxy-homopregnacalciferol and its uses This invention discloses 2-methylene-18,19-dinor-vitamin D analogs, and specifically 2-methylene-18,19-dinor-1α-hydroxy-homopregnacalciferol and pharmaceutical uses therefor. This compound exhibits pronounced activity in arresting the proliferation of undifferentia... | 07/03/2007 |
| RE39706 | Crystalline form of a vitamin D analogue The present invention relates to calcipotriol hydrate—a new crystalline form of calcipotriol—with superior technical properties and with superior stability. ... | 06/26/2007 |
| 7235680 | 2-methylene-19-nor-(23S)-25-dehydro-1α-hydroxyvitamin D-26,23-lactone and 2-methylene-19-nor-(23R)-25-dehydro-1α-hydroxyvitamin D-26,23-lactone Compounds of formula 1A and 1B are provided where X1 and X2 are independently selected from H or hydroxy protecting groups. Such compounds may be used in preparing pharmaceutical compositions and are useful in treating a variety of biological d... | 06/26/2007 |
| 7232810 | 2-methylene-19-nor-vitamin D2 compounds 2-Methylene-19-nor-24(S) and 24(R) derivatives of 1α,25-dihydroxyvitamin D2 are disclosed. These compounds are characterized by minimal bone calcium mobilization activity and relatively high intestinal calcium transport activity. This results in novel th... | 06/19/2007 |
| 7214671 | Use of 2-methylene-19-nor-20(S)-1α,25-dihydroxyvitamin Dfor the prophylaxis of bone diseases This invention provides pharmaceutical uses for 2-methylene-19-nor-20(S)-1α,25-dihydroxyvitamin D3. This compound is characterized by high bone calcium mobilization activity demonstrating preferential activity on bone. This results in a novel therapeutic... | 05/08/2007 |
| 7214670 | Use of 2-methylene-19-nor-20(S)-1α,25-dihydroxyvitamin Dto increase the life expectancy of human beings This invention provides pharmaceutical uses for 2-methylene-19-nor-20(S)-1α,25-dihydroxyvitamin D3. Administration of this compound increases the life expectancy of human beings, especially elderly human beings. In particular, it increases the survival r... | 05/08/2007 |
| 7211172 | Method of photochemical synthesis of vitamin Ds An enhanced photochemical method of making vitamin D includes irradiating a reaction mixture of precursor molecules with light having a wavelength of 254 nm and with light having a wavelength of 313 nm to produce previtamin D, and is followed by heating at a tempera... | 05/01/2007 |
| 7211680 | Vitamin D derivatives with carbo-or heterocyclic substituents at C-25, a process for their production, intermediate products and their use for producing medicaments Compounds of Formula I, wherein Y1, Y2, R1–R6, Q and Z are as defined herein, are vitamin D derivatives. These compounds are useful for, e.g., the treatment hyperprol... | 05/01/2007 |
| 7208484 | Method of synthesizing 1alpha-hydroxy-2-methylene-19-nor-homopregnacalciferol A method of making 1α-hydroxy-2-methylene-19-nor-homopregnacalciferol. The method includes the steps of condensing a bicyclic ketone with an allylic phosphine oxide to produce a protected 19-nor-pregnacalciferol analog, thereafter cleaving the protecting group to f... | 04/24/2007 |
| 7205286 | (20S)-1α-hydroxy-2α-methyl and 2β-methyl-19-nor-vitamin Dand their uses This invention discloses (20S)-1α-hydroxy-2α-methyl-19-nor-vitamin D3 and (20S)-1α-hydroxy-2β-methyl-19-nor-vitamin D3 and pharmaceutical uses therefor. These compounds exhibit pronounced activity in arresting the proliferation of undiffere... | 04/17/2007 |
| 7205420 | Epimerization of analogs of vitamin D Provided is a method of general applicability of epimerizing a vitamin-D analog having an asymmetric allylic carbon atom at the C-24 position. The method is of particular utility in making calcipotriene. ... | 04/17/2007 |
| 7166585 | 24-Sulfur-substituted analogs of 1α,25-dihydroxy vitamin D The present invention provides novel C24-sulfone analogs of 1α,25-dihydroxy vitamin D3, compositions comprising these compounds and methods of using these compounds as selective inhibitors of CYP24. In particular, the compounds of the invention are usefu... | 01/23/2007 |
| 7141558 | 2-ethyl and 2-ethylidene-19-nor-vitamin D compounds Biologically active 19-nor vitamin D analogs substituted at C-2 in the A-ring with an ethylidene or an ethyl group. These compounds have preferential activity on mobilizing calcium from bone and either high or normal intestinal calcium transport activity which allow... | 11/28/2006 |
| 7122533 | Cosalane compounds and methods for their use The present invention relates to methods, compounds and compositions for inhibiting effective binding of a chemokine to its cellular receptor. In one form of the invention, a method includes contacting a cellular population with an effective amount of cosalane or an... | 10/17/2006 |
| 7115758 | Vitamin D derivatives with cyclic substructures in the side chains, process and intermediate products for their production, and the use for the production of pharmaceutical agents The invention relates to vitamin D derivatives of general formula I, process for their production, intermediate products of the process as well as the use for the production of pharmaceutical agents. ... | 10/03/2006 |
| 7112579 | 26,27-Homologated-20-EPI-2-alkyl-19-nor-vitamin D compounds This invention provides a novel class of vitamin D related compounds, namely, the 2-alkyl-19-nor-vitamin D derivatives, as well as a general method for their chemical synthesis. The compounds have the formula: wh... | 09/26/2006 |
| 7101865 | 24-sulfoximine vitamin D3 compounds The present invention provides novel sulfoximine compounds, compositions comprising these compounds and methods of using these compounds as inhibitors of CYP24. In particular, the compounds of the invention are useful for treating diseases which benefit from a modul... | 09/05/2006 |
| 7094775 | Method of treating breast cancer using a combination of vitamin D analogues and other agents The invention provides therapeutic methods for inhibiting, ameliorating or alleviating the hyperproliferative cellular activity of diseases of the breast, e.g., breast cancer, which includes administering to a patient in need thereof an active vitamin D analogue and... | 08/22/2006 |
| 7094916 | (20S)-1α-hydroxy-2α-methyl and 2β-methyl-19-nor-vitamin Dand their uses This invention discloses (20S)-1α-hydroxy-2α-methyl-19-nor-vitamin D3 and (20S)-1α-hydroxy-2β-methyl-19-nor-vitamin D3 and pharmaceutical uses therefor. These compounds exhibit pronounced activity in arresting the proliferation of undiffere... | 08/22/2006 |
| 7094774 | 26,27-homologated-20-epi-2-alkylidene-19-nor-vitamin D compounds This invention provides a novel class of vitamin D related compounds, namely, the 2-alkylidene-19-nor-vitamin D derivatives, as well as a general method for their chemical synthesis. The compounds have the formula: | 08/22/2006 |
| 7094776 | Method of locking 1α-OH of vitamin D compounds in axial orientation A method of modifying or altering the structure of a 1α-hydroxylated vitamin D compound to increase its biological activity by altering the conformational equilibrium of the A-ring to favor a chair conformation that presents the 1α-hydroxyl in the axial orientatio... | 08/22/2006 |
